Expert insights into the contemporary management of older adults with acute myeloid leukemia.

about

Expert insights into the contemporary management of older adults with acute myeloid leukemia.

Item

http://www.wikidata.org/entity/Q44898238

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Expert insights into the conte ...... s with acute myeloid leukemia.

@en

Expert insights into the conte ...... s with acute myeloid leukemia.

@nl

type

Item

label

Expert insights into the conte ...... s with acute myeloid leukemia.

@en

Expert insights into the conte ...... s with acute myeloid leukemia.

@nl

prefLabel

Expert insights into the conte ...... s with acute myeloid leukemia.

@en

Expert insights into the conte ...... s with acute myeloid leukemia.

@nl

P1476

Expert insights into the conte ...... s with acute myeloid leukemia.

@en

P2093

Daniel A Pollyea

http://www.w3.org/2001/XMLSchema#string

Harry P Erba

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Cancer statistics, 2013

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.

P304

5-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/107327481302004S02

http://www.w3.org/2001/XMLSchema#string

P433

4 Suppl

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Farhad Ravandi

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24077448

http://www.w3.org/2001/XMLSchema#string

P921

leukemia